1. Achieving Minimal Residual Disease (MRD) negativity at baseline before lenalidomide maintenance, and at one-year post Auto-HCT (AutoHCT) predicts increased...

1. The objective response rate for trastuzumab deruxtecan was 29.4%. 2. Treatment-emergent adverse event grade 3 or higher was seen...

1. Although capecitabine or XELOX did not improve overall survival when compared to PF, efficacy was comparable suggesting single-agent capecitabine...

1. Lymphoid malignancy survival rates in European countries correlate with national health expenditure level. 2. Geographic disparities in lymphoid malignancy...

1. The median overall survival was 17.6 months in the gefitinib group vs 27.5 months in the gefitinib plus chemotherapy...

1. For patients with localized endometrial cancer recurrence, adding cisplatin to radiation therapy did not appear to improve progression-free survival...

1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with...

1. Mitoxantrone enhances five-year event-free survival over liposomal daunorubicin in MRD-guided pediatric AML treatment. 2.High-risk patients identified by MRD guidance...

1. The hazard ratio for recurrence or death comparing sentinel node biopsy only to completion axillary lymph node dissection was...

1. When compared to upfront surgery, neoadjuvant chemotherapy using mFOLFOX or CAPOX did not appear to significantly improve 3-year disease-free...